| Name | Title | Contact Details |
|---|
IMUNON is a fully integrated, clinical stage biotechnology company focused on advancing a portfolio of innovative treatments that harness the bodys natural mechanisms to generate safe, effective, and durable responses across a broad array of human diseases. IMUNON has two platform technologies: Our TheraPlas® platform for the development of immunotherapies and other anti-cancer nucleic acid-based therapies and our PLACCINE platform for the development of nucleic acid vaccines for infectious diseases and cancer. The Companys lead clinical program, GEN-1, is a DNA-based immunotherapy for the localized treatment of advanced ovarian cancer currently in Phase II development. GEN-1 works by instructing the body to produce safe and durable levels of powerful cancer fighting molecules, such as interleukin-12 (IL-12) and interferon gamma (IFN-γ), at the tumor site. In addition, we are conducting pre-clinical proof-of-concept studies on a nucleic acid vaccine candidate targeting SARS-CoV-2 virus in order to validate our PLACCINE platform. IMUNONs platform technologies are based on the delivery of nucleic acids with novel synthetic delivery systems that are independent of viral vectors or devices. We will continue to leverage these platforms and to advance the technological frontier of plasmid DNA to better serve patients with difficult to treat conditions.
ADEC Innovations seamlessly delivers fully integrated, cost-effective industry expertise, business process & data management, and software services. Our mission: to ensure we meet your ever-evolving ESG needs and help you improve sustainability performance, gain unprecedented insights, optimize resource use, and drive operational efficiencies. With a global force of over 3,500 employees, our presence spans five continents – Asia, Australia, Europe, Africa and North America. We offer a wide range of solutions and consulting services across multiple fields, providing industry expertise in sustainability, environmental data services, knowledge management, data management, health information, and public-private partnerships. In all these business areas, we focus on aggregating, organizing and giving visibility to data in order to enable client organizations leaders and stakeholders to make informed decisions. Our comprehensive suite of ESG Solutions assist organizations in minimizing negative social and environmental impacts, maximize efficiency, and drive long-term business growth through sustainable profitability and empowered decision making.
Herspiegel is a consulting firm based in Pennsylvania, founded in 2007, that specializes in pharmaceutical and biotech commercialization services. With over fifteen years of experience, the company has supported more than 150 product launches across various therapeutic areas, including primary care, oncology, and rare diseases. Their mission is to create a model for successful pharmaceutical product launches. The firm offers a wide range of services tailored to the life sciences industry, including market access, medical affairs, marketing strategy, and operational execution. Herspiegels team consists of over 350 experts, including MDs, PhDs, MBAs, and pharmacists, who provide deep knowledge to help clients navigate complex challenges and maximize brand potential. They serve a diverse clientele, from startups to large global pharmaceutical companies, focusing on strategic insights and operational excellence to enhance commercial success and patient outcomes. Herspiegel has also expanded its capabilities through strategic acquisitions, such as Decisive Consulting, which enhances their market access and value strategy services. This positions Herspiegel to deliver innovative solutions in a dynamic pharmaceutical landscape.
Purem by Eberspächer is a global leader in exhaust technology and acoustic solutions, dedicated to advancing clean and quiet mobility for both passenger cars and commercial vehicles. As part of the Eberspächer Group, the company operates around 35 manufacturing sites and 40 development facilities across four continents, employing approximately 7,500 people, with a strong focus on exhaust technology. The company specializes in emission control products, including catalytic converters, particulate filters, and complete exhaust systems designed to reduce pollutants and meet global emissions standards. Additionally, Purem offers lightweight acoustic solutions to comply with noise regulations. With three R&D centers located in Germany, the USA, and China, the company is committed to innovation, holding around 2,000 patents and utilizing advanced development processes. Purem prioritizes sustainability through the use of lightweight materials and energy-efficient manufacturing practices, aligning with its vision of driving the mobility of tomorrow.